

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Stanton et al.)	Group Art Unit:	1647	
)			
Serial No.:	09/641,802)	Examiner:	Christopher Nichols	
Confirmation	No.: 5387)		•	
)			
Filed:	August 17, 2000)			
)			
For:	USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND				
	ANALOGS THEREOF TO PROMOTE NEURONAL CELL				
	DIFFERENTIATION				

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 et. seq., the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Supplemental Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Applicants also wish to bring the Examiner's attention to the following pending U.S. Applications, as well as any documents, Office Actions that may include rejections of similar claims, and any provisional U.S. patent applications referenced in the pending U.S. applications or in their file wrappers. A copy of each of the below-listed pending U.S. Patent Applications is provided herewith.

Applicant(s): Stanton et al. Serial No.: 09/641,802 Confirmation No.: 5387 Filed: August 17, 2000

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF TO

PROMOTE NEURONAL CELL DIFFERENTIATION

List of Pending Non-Published U.S. Patent Applications

Applicant(s)	Application Number	Filing Date	Serial No. of Provisional Application to which listed Application claims priority
Boldogh et al.	10/691,330	October 22, 2003	60/420,369
Boldogh et al.	10/691,157	October 22, 2003	60/149,310 and 60/420,369

Since this Supplemental Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, please charge Deposit Account No. 13-4895 the amount of \$180 under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

The Examiner is invited to contact Applicants' Representatives at the belowlisted telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Sava E. OUSON
"Express Mail" mailing label number:

EV 201890365 US Date of Deposit: May 17, 20

May 17, 2004

Date

Respectfully submitted for **Stanton et al.**

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220 Facsimile: (612)305-1228 Customer Number 26813

Nancy A. Johnson

Reg. No. 47,266

Direct Dial (612)305-4723